Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia

Recruiting now · Not applicable

Conditions studied: Bladder Cancer

In brief

Analysis of the efficacy and the compatibility of deep regional hyperthermia in combination with radiotherapy and chemoradiotherapy in bladder cancer

Key facts

Study ID

NCT05397262

Run by

University of Erlangen-Nürnberg Medical School

People needed

1000

Starts

2017-03-29

Expected to finish

2099-12-31

Last updated by the study team

2024-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Histologically confirmed bladder cancer
• M0
• ECOG-performance status ≤ 2
• Informed consent

You may not qualify if…

• Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy
• Cardiac Pacemaker
• Myocardial infarction within the past 12 months
• Congestive heart failure
• Complete bundle branch block
• New York Heart Association (NYHA) class III or IV heart disease
• Disease that would preclude TUR, chemoradiation or deep regional hyperthermia
• Metal implants (lenght > 2cm or dense clusters of marker clips in the pelvis)
• Active or therapy-resistent bladder infections
• Pre-existing or concommitant immunodeficiency Syndrom
• Pregnant or lactating women
• Patients not willing to use effective contraception during and up to 6 months after therapy

Where it is running

• Dept. of Radiation Therapy, University Hospital Erlangen — Erlangen, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.